Compared to vaginal delivery, cesarean delivery has greater risk of maternal severe morbidity and mortality. The international healthcare community has defined an ideal prevalence of cesarean delivery to be between 10% to 15%. Currently in the United States, one in three women give birth by cesarean delivery.
Several approaches have been used to decrease the prevalence of cesarean delivery. One of the main strategies includes the prevention of primary cesarean delivery, which decreases long-term risks and lowers the repeat cesarean delivery rate. ACOG summarizes recommendations to safely avoid the first cesarean section.
Most common indications for cesarean delivery (starting with most frequent) include
ACOG states that
Because they are contemporary and robust, it seems that the Consortium on Safe Labor data, rather than the standards proposed by Friedman, should inform evidence-based labor management
Note: There is an association between duration of first stage of labor and chorioamnionitis, but causality is unclear
Note: Use of an algorithm, such as the Shields algorithm or Clark algorithm, may help guide management of Category II tracings (see ‘Primary Sources – Learn More’ below)
Elective Induction of Labor at 39 weeks
Note: Allow 24 h or more in the latent phase before diagnosing failed induction | Rupture of membranes and oxytocin for 12 to 18 hours must be present prior to diagnosis of failed induction
Excessive Maternal Weight Gain
Herpes Simplex Virus
Organizational level interventions
Are you an
Get specially curated clinical summaries delivered to your inbox every week for free
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site